Peptides and related molecules that bind to TALL-1

Details Peptides and related molecules that bind to TALL-1 Peptides and related molecules that bind to TALL-1

2005-11-10

2010-06-15

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S324000

Reexamination Certificate

active

07737111

ABSTRACT:
The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4wherein z2is an amino acid residue and z4is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae(SEQ. ID. NO:100)a1a2a3CDa6La8a9a10Ca12a13a14,(SEQ. ID. NO:104)b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18(SEQ. ID. NO:105)c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18(SEQ. ID. NO:106)d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18(SEQ. ID. NO:107)e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18(SEQ. ID NO:109)f1f2f3Kf5Df7Lf9f10Qf12f13f14wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formulain-line-formulae description="In-line Formulae" end="lead"?(X1)a—V1—(X2)bin-line-formulae description="In-line Formulae" end="tail"?wherein V1is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

REFERENCES:
patent: 4496689 (1985-01-01), Mitra
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5593676 (1997-01-01), Bhat et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 5969102 (1999-10-01), Bram et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 0 869 180 (1998-10-01), None
patent: 0 526 452 (2001-02-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/27114 (1998-06-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 98/55621 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12964 (1999-03-01), None
patent: WO 99/25044 (1999-05-01), None
patent: WO 99/35170 (1999-07-01), None
patent: WO 9962951 (1999-12-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/47740 (2000-08-01), None
patent: WO 00/67034 (2000-11-01), None
patent: WO 00/68378 (2000-11-01), None
patent: WO 01/02440 (2001-01-01), None
patent: WO 01/85782 (2001-11-01), None
patent: WO 02/16411 (2002-02-01), None
patent: WO 02/16412 (2002-02-01), None
Chirinos-Rojas, C. L., et al., “ A Phage-Displayed Mimotope Inhibits Tumour Necrosis Factor—Inducted Cytotoxicity More Effectively Than the Free Mimotope,” Immunology 96:109-113 (1999).
Cwirla et al. (1997), “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine,”Science276: 1696-1699.
Devlin et al. (1990), “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,”Science249: 404-406.
Gross et al. (2000), “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-cell Autoimmune Disease,”Nature404: 995-999.
Gruss et al. (1995), “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas,”Blood85(12): 3378-3404.
Hatzoglou et al. (2000), “TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activiated Protein Kinase,”J. of Immunology165: 1322-1330.
Khare et al. (2000), “Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice,”PNAS97(7):3370-3375.
Lowman (1997), “Bacteriophage Display and Discovery of Peptide Leads for Drug Development,”Ann. Rev. Biophys. Biomol. Struct. 26: 401-424.
Marsters et al. (2000), “Interaction of the TNF Homologues B1yS and APRIL with the TNF Receptor Homologues BCMA and TACI,”Current Biology10(13):785-788.
Roberts & Szostak (1997), “RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins,”Proc. Natl. Acad. Sci. USA, 94: 12297-12302.
Scott et al. (1990), “Searching for Peptide Ligands with an Epitope Library,”Science249: 386-390.
Shu et al. (1999), “TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens,”J. Leukocyte Biol. 65:680-683.
Shu et al. (2000), “B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1,”PNAS97(16):9156-9161.
Smith et al. (1994), “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell76: 959-962.
Takasaki et al. (1997), “Structure-based Design and Characterization of Exocyclic Peptidomimetics that Inhibit TNFα Binding to its Receptor,”Nature Biotech. 15: 1266-1270.
Thompson et al. (2000), “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population,”J. Exp. Med. 192(1):129-135.
Ware (2000), “APRIL and BAFF Connect Autoimmunity and Cancer,”J. Exp. Med. 192(11): F35-F37.
Ware (2000), “Decoy Receptors Thwart B Cells,”Nature404: 949-950.
Wells & Lowman (1992), “Rapid Evolution of Peptide and Protein Binding Properties in vitro,”Curr. Opin. Biotechnol. 3: 355-362.
Xia et al. (2000), “TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation,”J. Exp. Med. 192(1):137-143.
Yu et al. (2000), “APRIL and TALL-1 and Receptors BCMA and TACI: System for Regualting Humoral Immunity,”Nature Immunology1(3):252-256.
Tan et al. (2002), “Local Production of B Lymphocyte Stimulator (BlyS™) Protein in Human Arthritic Joints,”abstract.
Cheema et al. (2002), “Increased B Lymphocyte Stimulator (BlyS™) Protein in HIV-Patients: Correlation with Anti-Cardiolipin (aCL) and Anti-Phospholipid (aPL) Autoantibodies,”abstract.
Sekut et al. (2002), “Characterization of a Human Monoclonal Antibody that Antagonizes B-Lymphocyte Stimulator Bioactivies,”abstract.
Zhang et al. (2001), “Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus,”J. Immunology166:6-10.
Oren et al. (2002), “Structural Basis of BlyS Receptor Recognition,”Nature Structural Biology9(4): 288-292.
Cheema et al. (2001), “Elevated Serum B Lymphocyte Stimulator Levels in Patients With Systemic Immune—Based Rheumatic Diseases,”Arthritis&Rheumatism44(6):1313-1319.
Mukhopadhyay et al. (1999), “Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-κB, and c-June NH2-Terminal Kinase,”J. Biol. Chem. 274(23): 15978-15981.
Database PNAS, Shu, H.-B. et al. “B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1,” Proc. Natl. Acad. Sci. USA. Aug. 1, 2000, vol. 97, No. 16, pp. 9156-9161.
Database PNAS, Khare, et al. “Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenis mice,” Proc. Natl. Acad. Sci. USA. Mar. 28, 2000, vol. 97, No. 7, pp. 3370-3375.
Samoylova et al. (2003), “Phage probes for malignant glial cells,”Mol. Cancer Ther. 2:1129-1137.

Affiliated with

Also associated with

Rating

Peptides and related molecules that bind to TALL-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and related molecules that bind to TALL-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and related molecules that bind to TALL-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4167616